Milton Barros

Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation

N. Chanson, Manuel Ramos‐Casals, Xerxes Pundole et al. · European Journal of Cancer · 2021 · 50 citations

Immune Checkpoint, Benign Disease, Autoimmune Disease +11

A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma

Rodrigo Ramella Munhoz, Guilherme Nader Marta, Veridiana Pires de Camargo et al. · Cancer · 2022 · 46 citations

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Rik J. Verheijden, F.H. Burgers, Josephine C Janssen et al. · European Journal of Cancer · 2024 · 44 citations · Full text

Checkpoint Inhibitor Effectiveness, Medicine, Melanoma +10

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil

Andréia Cristina de Melo, Vanessa Karen de Sá, Cinthya Sternberg et al. · Oncology · 2015 · 34 citations

Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms

Rodrigo Gomes Taboada, Laura Carolina López Claro, Tiago Cordeiro Felismino et al. · Journal of Neuroendocrinology · 2022 · 24 citations